Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/57083
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond
Other Titles: Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO(.) and beyond
Author: Ritchie, R.
Irvine, J.
Rosenkranz, A.
Patel, R.
Wendt, I.
Horowitz, J.
Kemp-Harper, B.
Citation: Pharmacology and Therapeutics, 2009; 124(3):279-300
Publisher: Pergamon-Elsevier Science Ltd
Issue Date: 2009
ISSN: 0163-7258
1879-016X
Statement of
Responsibility: 
Rebecca H. Ritchie, Jennifer C. Irvine, Anke C. Rosenkranz, Ruchi Patel, Igor R. Wendt, John D. Horowitz and Barbara K. Kemp-Harper
Abstract: Left ventricular hypertrophy (LVH), an increased left ventricular (LV) mass, is common to many cardiovascular disorders, initially developing as an adaptive response to maintain myocardial function. In the longer term, this LV remodelling becomes maladaptive, with progressive decline in LV contractility and diastolic function. Indeed LVH is recognised as an important blood-pressure independent predictor of cardiovascular morbidity and mortality. The clinical efficacy of current treatments for LVH is reduced, however, by their tendency to slow disease progression rather than induce its reversal, and thus the development of new therapies for LVH is paramount. The signalling molecule cyclic guanosine-3',5'-monophosphate (cGMP), well-recognised for its role in regulating vascular tone, is now being increasingly identified as an important anti-hypertrophic mediator. This review is focused on the various means by which cGMP can be stimulated in the heart, such as via the natriuretic peptides, to exert anti-hypertrophic actions. In particular we address the limitations of traditional nitric oxide (NO*) donors in the face of the potential therapeutic advantages offered by novel alternatives; NO* siblings, ligands of the cGMP-generating enzymes, soluble (sGC) and particulate guanylyl cyclases (pGC), and phosphodiesterase inhibitors. Further impact of cGMP within the cardiovascular system is also discussed with a view to representing cGMP-based therapies as innovative pharmacotherapy, alone or concurrent with standard care, for the management of LVH.
Keywords: Cardiomyocyte
Cyclic GMP
Guanylyl cyclase
Myocardium
Nitric oxide
Natriuretic peptides
Rights: Copyright © 2009 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.pharmthera.2009.08.001
Published version: http://dx.doi.org/10.1016/j.pharmthera.2009.08.001
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.